-logo.jpg "Shionogi Inc. (U.S.)"){kind=logo}
United States
Shionogi Inc. (U.S.), founded in 2001, is a significant player in the pharmaceutical industry, driven by a mission to supply the best possible medicines to protect patient health and well-being. With roots extending back to 1878, the company is a pioneer in addressing critical global health challenges such as antimicrobial resistance and COVID-19.
Boasting a rich history, Shionogi has been at the forefront of novel antibiotic discoveries since the 1950s and has introduced innovative treatments for HIV and influenza. Presently, Shionogi is advancing research with an investigational oral antiviral for COVID-19 and developing solutions for Fragile X syndrome, acute ischemic stroke, and metabolic disorders, alongside oncology advancements.
The company's collaborative approach merges in-house discovery efforts with partnerships across industry, government, biotech, and academia. This strategy reflects their commitment to advancing science underpinned by urgency. Although specific investment figures are undisclosed, Shionogi's track record positions it as a compelling equity opportunity.
